Gabriela Alperovich
Executive Director, Medical, Cardiovascular & Renal, Global Clinical Lead CSL
Seminars
Thursday 20th August 2026
Fireside Discussion: From Asset Evaluation to Integration: How Strategic Dealmaking Accelerates Rare Kidney Disease Drug Development
3:30 pm
- Evaluating rare kidney disease assets: What factors beyond clinical stage influence portfolio fit and investment decisions
- Cross-functional diligence in action: How business development, clinical, regulatory, and safety teams collaborate to assess opportunities under tight timelines
- From deal to development: Best practices for integrating newly acquired programs and maintaining momentum in clinical trials for diseases such as IgA Nephropathy and Focal Segmental Glomerulosclerosis
